Table 2.
Contact brachytherapy, customized molds and flaps, Leipzig and Valencia applicators, combination of techniques.
| Author | Year | Histology | N. Lesions N. patients | Dose rate | N. Fractions | Dose/ Fraction | Frequency | Total Dose | Technique | Follow-up (median) | Local control |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Svoboda et al. (71) | 1995 | BCC (76) SCC (11) Lymphomas (2) Bowen's disease (9) Other (8) |
106 lesions 76 patients | HDR | 1–15 | 3.3–22 Gy | Daily/Twice a day/Weekly | 12–50 Gy 27–50 Gy |
Molds | 9.6 months | 100% |
| Allan et al. (72) | 1998 | BCC (9) SCC (3) Other (1) |
13 patients | HDR | 8 | 5–5.5 Gy | In five days, 1–2 times daily | 42.5–45 Gy | Molds | 18 months | 100% |
| Köhler-Brock et al. (73) | 1999 | BCC SCC Kaposi's sarcoma Lymphomas Melanomas |
520 lesions 520 patients | HDR | 4–8 | 5–10 Gy | 1–2 times a week | 30–40 Gy | Surface applicators | 10 years | 91% |
| Guix et al. (74) | 2000 | BCC (102) SCC (34) |
136 lesions 136 patients | HDR | 33–36 | 1.8 Gy | Daily | 60–65 Gy 75–80 Gy | Molds | 5 years | 87–98% |
| Skowronek et al. (75) | 2005 | BCC (35) SCC (20) Other (10) |
179 lesions 179 patients | HDR | 5–6 | 10 Gy | 1–2 times a week | 50–60 Gy | Molds/Flaps | 12 months | 82% |
| Ghaly et al. (76) | 2008 | BCC (35) SCC (20) Other (10) |
65 lesions 59 patients | HDR | 3–30 | 2–5 Gy | Daily/Twice a day | 40 Gy | Flaps/Surface applicators | 18 months | 96% |
| Somanchi et al. (77) | 2008 | SCC | 25 lesions 25 patients | HDR | 8 | 5–5.6 Gy | In five days, 1–2 times a day | 40–45 Gy | Molds | 60 months | 100% |
| Kanikowski et al. (78) | 2009 | BCC (233) SCC (118) Other (146) |
497 lesions 497 patients | HDR | 10 6–8 |
5–6 Gy 5 Gy |
- | 50–60 Gy 30–40 Gy |
Molds/Surface applicators | 12 months | 72% |
| Maroñas et al. (79) | 2011 | Cutaneous carcinoma | 45 lesions 32 patients | HDR | 5–18 | 3–7 Gy | Daily/ 3 times a week | 44–57 Gy | Molds/ Flaps | 45 months | 83–100% |
| Gauden et al. (80) | 2013 | BCC (121) SCC (115) |
236 lesions 200 patients | HDR | 12 | 3 Gy | Daily | 36 Gy | Surface applicators | 66 months | 98% |
| Tormo et al. (81) | 2014 | BCC (45) | 45 lesions 32 patients | HDR | 6–7 | 6–7 Gy | Twice a week | 42 Gy | Surface applicators | 47 months | 98% |
| Arenas et al. (82) | 2015 | BCC (92) SCC (42) |
134 lesions 114 patients | HDR | 15–19 | 3 Gy | 3 times a week | 45–57 Gy | Molds/Surface applicator | 33 months | 95% |
| Delishaj et al. (83) | 2015 | BCC (44) SCC (12) Kaposi's sarcoma (1) |
57 lesions 39 patients | HDR | 8–10 | 5 Gy | 2–3 times a week | 40–50 Gy | Surface applicators | 12 months | 96% |
| Amendola et al. (84) | 2016 | NMSC | 42 lesions 38 patients | HDR | 10 | 4.85–5 Gy | 2 times a week | 48.5–50 Gy | Molds | 85 months | 95% |
| Jumeau et al. (85) | 2016 | NMSC (5) Sarcoma (5) Neuroendocrine carcinoma (2) |
12 lesions 11 patients | HDR | 1–5 | 5–8 Gy | Twice a week | 8–30 Gy | Molds/Flaps | 17 months | 91% |
| Kalaghchi et al. (86) | 2018 | BCC (45) SCC (15) |
60 lesions 60 patients | HDR | 10–13 | 3–4 Gy | Daily | 30–52 Gy | Molds | 24 months | 88–95% |
| Casey et al. (87) | 2019 | BCC (35) SCC (20) |
65 lesions 59 patients | HDR | 3–30 | 3–5 Gy | Daily | 15–60 Gy | Molds | 8 months | 92% |
| Laliscia et al. (88) | 2021 | BCC (23) SCC (14) |
40 lesions 37 patients | HDR | 8 | 5 Gy | 2–3 times a week | 25–50 Gy | Molds | 25 months | 90% |